Varela-Rey Iria, Bandín-Vilar Enrique, Toja-Camba Francisco José, Cañizo-Outeiriño Antonio, Cajade-Pascual Francisco, Ortega-Hortas Marcos, Mangas-Sanjuan Víctor, González-Barcia Miguel, Zarra-Ferro Irene, Mondelo-García Cristina, Fernández-Ferreiro Anxo
Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain.
Antibiotics (Basel). 2024 Dec 10;13(12):1203. doi: 10.3390/antibiotics13121203.
The use of artificial intelligence (AI) and, in particular, machine learning (ML) techniques is growing rapidly in the healthcare field. Their application in pharmacokinetics is of potential interest due to the need to relate enormous amounts of data and to the more efficient development of new predictive dose models. The development of pharmacokinetic models based on these techniques simplifies the process, reduces time, and allows more factors to be considered than with classical methods, and is therefore of special interest in the pharmacokinetic monitoring of antibiotics. This review aims to describe the studies that use AI, mainly oriented to ML techniques, for dose prediction and analyze their results in comparison with the results obtained by classical methods. Furthermore, in the review, the techniques employed and the metrics to evaluate the precision are described to improve the compression of the results. : A systematic search was carried out in the EMBASE, OVID, and PubMed databases and the results obtained were analyzed in detail. : Of the 13 articles selected, 10 were published in the last three years. Vancomycin was monitored in seven and none of the studies were performed on new antibiotics. The most used techniques were XGBoost and neural networks. Comparisons were conducted in most cases against population pharmacokinetic models. : AI techniques offer promising results. However, the diversity in terms of the statistical metrics used and the low power of some of the articles make the overall assessment difficult. For now, AI-based ML techniques should be used in addition to classical population pharmacokinetic models in clinical practice.
人工智能(AI),尤其是机器学习(ML)技术在医疗保健领域的应用正在迅速增长。由于需要关联大量数据以及更高效地开发新的预测剂量模型,它们在药代动力学中的应用具有潜在的研究价值。基于这些技术开发药代动力学模型简化了流程,减少了时间,并允许比传统方法考虑更多的因素,因此在抗生素的药代动力学监测中具有特殊意义。本综述旨在描述使用AI(主要是ML技术)进行剂量预测的研究,并将其结果与传统方法获得的结果进行比较分析。此外,在综述中,还描述了所采用的技术和评估精度的指标,以改进对结果的理解。:在EMBASE、OVID和PubMed数据库中进行了系统检索,并对获得的结果进行了详细分析。:在所选的13篇文章中,有10篇是在过去三年发表的。有7项研究监测了万古霉素,没有一项研究针对新型抗生素。最常用的技术是XGBoost和神经网络。在大多数情况下,与群体药代动力学模型进行了比较。:AI技术提供了有前景的结果。然而,所用统计指标的多样性以及部分文章的低效能使得整体评估变得困难。目前,在临床实践中,基于AI的ML技术应与传统的群体药代动力学模型一起使用。